Stock RBSH REBUS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Rebus Holdings, Inc.

Equities

RBSH

US75619J1034

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 18:56:51 20/05/2024 BST 		5-day change 1st Jan Change
0.000001 USD -99.00% Intraday chart for Rebus Holdings, Inc. -.--% -.--%
2023 Rebus Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
2023 Rebus Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 0.2391 0.0445 0.0581 0.9112 0.2742 0.241
Enterprise Value (EV) 1 2.705 2.641 2.88 2.385 0.0772 0.546
P/E ratio - - - -0.04 x -0.4 x -0.23 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -0.81 x -3.75 x -5.03 x -5.01 x - -
EV / FCF -32.5 x -2.84 x 20.6 x 0.49 x -0.01 x -0.79 x
FCF Yield -3.08% -35.3% 4.85% 205% -8,155% -127%
Price to Book - - - -0.09 x -0.06 x -0.05 x
Nbr of stocks (in thousands) 0.17 0.19 5.06 2,000 10,309 32,133
Reference price 2 1,406 230.6 11.48 0.4556 0.0266 0.007500
Announcement Date 26/04/19 06/08/19 14/05/20 31/03/21 31/03/22 31/03/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales - - - - - -
EBITDA 1 -3.32 -0.705 -0.573 -0.476 - -
EBIT 1 -3.36 -0.724 -0.609 -0.512 -1.022 -0.664
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -11.1 -0.012 -0.934 -6.295 2.698 -1.02
Net income 1 -11.1 -0.012 -0.934 -6.295 2.698 -1.02
Net margin - - - - - -
EPS - - - -11.00 -0.0663 -0.0321
Free Cash Flow 1 -0.0832 -0.9312 0.1398 4.899 -6.298 -0.6911
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 26/04/19 06/08/19 14/05/20 31/03/21 31/03/22 31/03/23
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 2.47 2.6 2.82 1.47 - 0.31
Net Cash position 1 - - - - 0.2 -
Leverage (Debt/EBITDA) -0.7428 x -3.682 x -4.925 x -3.097 x - -
Free Cash Flow 1 -0.08 -0.93 0.14 4.9 -6.3 -0.69
ROE (net income / shareholders' equity) 228% 0.14% 11% 59.3% -30.8% 19.9%
ROA (Net income/ Total Assets) -523% -208% -196% -150% -114% -115%
Assets 1 2.122 0.005768 0.4773 4.2 -2.363 0.8848
Book Value Per Share - - - -5.050 -0.4300 -0.1600
Cash Flow per Share - - - 0.1600 0.0600 0
Capex 1 0 - - - - -
Capex / Sales - - - - - -
Announcement Date 26/04/19 06/08/19 14/05/20 31/03/21 31/03/22 31/03/23
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
REBUS HOLDINGS, INC. Stock Rebus Holdings, Inc.
-.--% 32
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+19.12% 125B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+14.65% 108B
BIONTECH SE Stock BioNTech SE
-4.73% 24.57B
ARGENX SE Stock argenx SE
+3.23% 22.82B
GENMAB A/S Stock Genmab A/S
-10.44% 18.19B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.74% 16.54B
BEIGENE, LTD. Stock BeiGene, Ltd.
-12.56% 16.5B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.73% 13.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.63% 11.1B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RBSH Stock
  4. Financials Rebus Holdings, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW